Cohen Philip R, Schulze Keith E, Nelson Bruce R
Dermatologic Surgery Center of Houston, PA, Houston, Texas 77030, USA.
Dermatol Surg. 2006 Apr;32(4):542-51. doi: 10.1111/j.1524-4725.2006.32110.x.
Basal cell carcinoma with mixed histology (BCC-MH) demonstrates more than one pathologic pattern of tumor. Appropriate therapy for the nonaggressive tumor subtype diagnosed from a superficial biopsy may not be adequate to treat the unsuspected aggressive tumor subtype, resulting in recurrent skin cancer.
We prospectively evaluated the incidence and characteristics of BCC-MH.
Mohs surgical sections were evaluated for BCC-MH.
BCC-MH was observed in 43% (49/144) of cancers. Only 10% (5/49) of the biopsy reports from these cancers diagnosed BCC-MH. Most BCC-MH were previously untreated (90% [44/49] of tumors) and were located on the nose.
More than 40% of basal cell carcinomas referred for removal of the residual tumor were BCC-MH. An unsuspected aggressive pathologic pattern of growth may not be detected after a superficial biopsy. Subsequently, the cancer may recur if the initial treatment for the diagnosed nonaggressive tumor subtype is inadequate for the undiscovered aggressive carcinoma. Mohs micrographic surgery is recommended for BCC-MH treatment.
混合组织学基底细胞癌(BCC-MH)表现出不止一种肿瘤病理模式。从浅表活检诊断出的非侵袭性肿瘤亚型的适当治疗可能不足以治疗未被怀疑的侵袭性肿瘤亚型,从而导致皮肤癌复发。
我们前瞻性评估了BCC-MH的发病率和特征。
对莫氏手术切片进行BCC-MH评估。
在43%(49/144)的癌症中观察到BCC-MH。这些癌症的活检报告中只有10%(5/49)诊断出BCC-MH。大多数BCC-MH之前未接受过治疗(90%[44/49]的肿瘤),且位于鼻部。
因切除残留肿瘤而转诊的基底细胞癌中,超过40%为BCC-MH。浅表活检后可能无法检测到未被怀疑的侵袭性病理生长模式。随后,如果对已诊断的非侵袭性肿瘤亚型的初始治疗对未发现的侵袭性癌不充分,癌症可能会复发。建议采用莫氏显微外科手术治疗BCC-MH。